Prognostic gene expression signature for high-grade serous ovarian cancerJoshua Millstein, Scott D. Brown, Timothy Budden et al.|Annals of Oncology|2020Cited by 173
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)Aline Talhouk, Chloe Karpinskyj, Joshy George et al.|Clinical Cancer Research|2020Cited by 79
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis ConsortiumFilipe Correia Martins, Michael Schneider, Dominique‐Laurent Couturier et al.|British Journal of Cancer|2020Cited by 68
Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp> CD8 <sup>+</sup> TIL </scp> infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomasKarolin Heinze, Yurii B. Shvetsov, Jessica Boros et al.|The Journal of Pathology|2021Cited by 42
Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian CarcinomaKarolin Heinze, Yurii B. Shvetsov, Tayyebeh M. Nazeran et al.|medRxiv|2021Cited by 4